In addition tp causing tremendous obstetric and neonatal morbidity, pregnancy-associated malaria may have lasting consequences for the development of immunity during childhood. It has long been known that the fetal immune system is predisposed toward development of tolerance upon exposure to foreign antigens. The biological mechanisms underlying this process are only beginning to be understood, but recent data support a novel model of """"""""layered"""""""" immune development, wherein the fetal immune system is populated during development by two distinct waves of lymphoid progenitor cells that differ in their intrinsic properties and developmental potential: """"""""fetal"""""""" T cells (Tf), which are tolerogenic, and """"""""adult"""""""" T cells (Ta), which are poised to mount effector responses. We propose to test this hypothesis by examining the consequences of in utero exposure to malaria antigens among infants born to women participating in two randomized trials of chemoprevention during pregnancy in a highly malaria-endemic region of Uganda. We hypothesize that fetal exposure to malaria antigens in utero can induce immune tolerance, which interferes with the later development of antimalarial immunity. We further hypothesize that infants with a Tf-skewed (predominantly tolerogenic) T cell compartment at birth will develop less robust Th1 responses and be slower to acquire natural immunity to malaria. In three aims, we will assess the relationship between in utero exposure to malaria antigens, the proportion of """"""""tolerogenic"""""""" fetal T cells present at birth (Tf:Ta ratio), and the frequency and function of malaria-specific effector T cells and FoxP3+ regulatory CD4 T cells in cord blood, and we will determine how these factors influence the T cell response to postnatal infection and the incidence of clinical malaria during the first 3 years of life. By performing longitudinal assessments of mother-infant pairs who are followed closely from mid-gestation through early childhood and differ only in their prenatal exposure to malaria antigens, the proposed investigations will test a novel paradigm for understanding human fetal immune ontogeny and will define the immune consequences of prenatal exposure to malaria, as well the potential of chemoprevention during pregnancy to enhance antimalarial immunity during childhood.

Public Health Relevance

The proposed studies will test the impact of enhanced chemoprevention during pregnancy on the development of antimalarial immunity during infancy, and will test a novel hypothesis for human fetal immune development. A better understanding ofthe mechanisms underlying fetal immune tolerance to malaria could lead to improved strategies to combat childhood malaria, and may also be of great importance for infant malaria vaccination strategies ,

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
2P01HD059454-06A1
Application #
8614266
Study Section
Special Emphasis Panel (ZRG1-AARR-D (42))
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-06-30
Support Year
6
Fiscal Year
2013
Total Cost
$418,219
Indirect Cost
$102,934
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Wallender, Erika; Vucicevic, Katarina; Jagannathan, Prasanna et al. (2018) Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis 217:964-972
Odorizzi, Pamela M; Jagannathan, Prasanna; McIntyre, Tara I et al. (2018) In utero priming of highly functional effector T cell responses to human malaria. Sci Transl Med 10:
Savic, Rada M; Jagannathan, Prasanna; Kajubi, Richard et al. (2018) Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis 67:1079-1088
Jagannathan, Prasanna; Kakuru, Abel; Okiring, Jaffer et al. (2018) Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med 15:e1002606
Jagannathan, Prasanna; Kajubi, Richard; Aweeka, Francesca T (2018) Response to ""Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction"". Clin Pharmacol Ther 103:571
Conroy, Andrea L; McDonald, Chloe R; Gamble, Joel L et al. (2017) Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Am J Obstet Gynecol 217:684.e1-684.e17
Kapisi, James; Kakuru, Abel; Jagannathan, Prasanna et al. (2017) Relationships between infection with Plasmodium falciparum during pregnancy, measures of placental malaria, and adverse birth outcomes. Malar J 16:400
Prahl, Mary; Jagannathan, Prasanna; McIntyre, Tara I et al. (2017) Sex Disparity in Cord Blood FoxP3+ CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero. Open Forum Infect Dis 4:ofx022
Sonoiki, Ebere; Nsanzabana, Christian; Legac, Jennifer et al. (2017) Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1. Antimicrob Agents Chemother 61:
Kajubi, R; Huang, L; Jagannathan, P et al. (2017) Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther 102:520-528

Showing the most recent 10 out of 59 publications